Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense ViewZacks Investment Research • 02/26/26
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressGlobeNewsWire • 02/25/26
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/24/26
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026GlobeNewsWire • 02/18/26
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptSeeking Alpha • 02/11/26
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billionWSJ • 01/09/26
Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To CircleSeeking Alpha • 01/09/26
Merck in Talks to Buy Revolution Medicines Per Financial Times ReportZacks Investment Research • 01/09/26
Revolution Medicines Announces FDA Breakthrough Therapy Designation for ZoldonrasibGlobeNewsWire • 01/08/26